Tecemotide

Summary

Tecemotide (CHEMBL3039544) is a phase-3 clinical-stage protein; indicated across 9 conditions including non-small cell lung carcinoma and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 9 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039544
Name	Tecemotide
Type	Protein
Max phase	3

Also known as: Blp 25, BLP-25, Blp-25 lipopeptide, BLP25, Blp25 lipopeptide, EMD 531444, Emepepimut-s, LIPOPEPTIDE BLP-25, Stimuvax, Tecemotida, Tecemotide, TECEMOTIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
breast neoplasm	3	MONDO:0021100	MONDO:0007254
rectal cancer	2	MONDO:0006519	EFO:1000657
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
colon carcinoma	2	MONDO:0002032	EFO:1001950
lung neoplasm	2	MONDO:0021117	MONDO:0008903
rectal neoplasm	2	MONDO:0002165	MONDO:0044937

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	4
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00409188	PHASE3	COMPLETED	Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
NCT00925548	PHASE3	TERMINATED	STRIDE - STimulating Immune Response In aDvanced brEast Cancer
NCT01015443	PHASE3	TERMINATED	Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
NCT02049151	PHASE3	TERMINATED	Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
NCT00157196	PHASE2	COMPLETED	Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
NCT00157209	PHASE2	COMPLETED	Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
NCT00828009	PHASE2	COMPLETED	BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00960115	PHASE1/PHASE2	COMPLETED	Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
NCT01094548	PHASE2	COMPLETED	Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
NCT01496131	PHASE2	COMPLETED	Tecemotide (L-BLP25) in Prostate Cancer
NCT01507103	PHASE2	COMPLETED	Tecemotide (L-BLP25) in Rectal Cancer
NCT01423760	Not specified	TERMINATED	Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).